Product

Bortezomib-bendamustine-melphalan

1 clinical trial

1 indication

Indication

Multiple Myeloma

Clinical trial

Bortezomib-bendamustine-melphalan vs High-dose Melphalan in Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma - a Single Center Retrospective Cohort Study

Status: Not yet recruiting, Estimated PCD: 2025-03-31